Eosinophilic gastroenteritis: epidemiology, diagnosis, and treatment.
Administration, Topical
Biomarkers
/ blood
Cytokines
/ blood
Diet Therapy
/ methods
Enteritis
/ diagnosis
Eosinophilia
/ diagnosis
Eosinophilic Esophagitis
/ diagnosis
Gastritis
/ diagnosis
Glucocorticoids
/ administration & dosage
Humans
Incidence
Interleukin-33
/ blood
Molecular Targeted Therapy
/ methods
Treatment Outcome
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
20
2
2020
medline:
4
9
2021
entrez:
20
2
2020
Statut:
ppublish
Résumé
Although several reviews concerning diagnosis and treatment of eosinophilic esophagitis (EoE) have been presented, there are few in regard to eosinophilic gastroenteritis (EGE). Fortunately, findings related to epidemiology, as well as diagnosis and treatment of this disease have recently been increasing. The rates of incidence of both EoE and EGE have been reported to be increasing. For accurate diagnosis, plasma concentrations of thymic stromal lymphopoietin and IL-33 may be useful as biomarkers, though consensus has not been reached, while increased eosinophil infiltration in gastrointestinal tissue remains a critical factor. Topical glucocorticoid administration, an elimination diet, and molecular target therapy with neutralizing antibodies are potentially effective therapies that have recently been evaluated. As seen with other allergic diseases, EGE seems to be increasing. Several research projects regarding diagnosis and treatment of the disease are currently in progress.
Identifiants
pubmed: 32073433
doi: 10.1097/ACI.0000000000000635
pii: 00130832-202006000-00016
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Glucocorticoids
0
IL33 protein, human
0
Interleukin-33
0
TSLP protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
311-315Références
Hui CK, Hui NK. A prospective study on the prevalence, extent of disease and outcome of eosinophilic gastroenteritis in patients presenting with lower abdominal symptoms. Gut Liver 2018; 12:288–296.
Pesek RD, Reed CC, Muir AB, et al. Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium. Am J Gastroenterol 2019; 114:984–994.
Mansoor E, Saleh MA, Cooper GS. Prevalence of eosinophilic gastroenteritis and colitis in a population-based study, from 2012 to 2017. Clin Gastroenterol Hepatol 2017; 15:1733–1741.
Ito J, Fujiwara T, Kojima R, Nomura I. Racial differences in eosinophilic gastrointestinal disorders among Caucasian and Asian. Allergol Int 2015; 64:253–259.
Jensen ET, Martin CF, Kappelman MD, Dellon ES. Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: estimates from a national administrative database. J Pediatr Gastroenterol Nutr 2016; 62:36–42.
Kinoshita Y, Furuta K, Ishimaura N, et al. Clinical characteristics of Japanese patients with eosinophilic esophagitis and eosinophilic gastroenteritis. J Gastroenterol 2013; 48:333–339.
Khoury P, Bochner BS. Consultation for elevated blood eosinophils: clinical presentations, high value diagnostic tests, and treatment options. J Allergy Clin Immunol Pract 2018; 6:1446–1453.
Mankad R, Bonnichsen C, Mankad S. Hypereosinophilic syndrome: cardiac diagnosis and management. Heart 2016; 102:100–106.
Ishimura N, Furuta K, Sato S, et al. Limited role of allergy testing in patients with eosinophilic gastrointestinal disorders. J Gastroenterol Hepatol 2013; 28:1306–1313.
Shoda T, Matsuda A, Arai K, et al. Sera of patients with infantile eosinophilic gastroenteritis showed a specific increase in both thymic stromal lymphopoietin and IL-33 levels. J Allergy Clin Immunol 2016; 138:299–303.
Ishihara S, Shoda T, Ishimura N, et al. Serum biomarkers for the diagnosis of eosinophilic esophagitis and eosinophilic gastroenteritis. Intern Med 2017; 56:2819–2825.
Lourenço LC, Horta DV, Reis J. Eosinophilic ascites: uncommon presentation of eosinophilic gastroenteritis in a young adult male. GE Port J Gastroenterol 2017; 24:206–208.
Nguyen N, Kramer RE, Friedlander JA. Videocapsule endoscopy identifies small bowel lesions in patients with eosinophilic enteritis. Clin Gastroenterol Hepatol 2018; 16:e64–e65.
Matsushita T, Maruyama R, Ishikawa N, et al. The number and distribution of eosinophils in the adult human gastrointestinal tract: a study and comparison of racial and environmental factors. Am J Surg Pathol 2015; 39:521–527.
Kiss Z, Tél B, Farkas N, et al. Eosinophil counts in the small intestine and colon of children without apparent gastrointestinal disease: a meta-analysis. J Pediatr Gastroenterol Nutr 2018; 67:6–12.
Hentschel F, Jansen AF, Günther M, et al. Eosinophil counts in mucosal biopsies of the ileum and colon: interobserver variance affects diagnostic accuracy. Patholog Res Int 2018; 2018:2638258.
Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology 2018; 155:1022–1033.e10.
Yang XM, He SQ, Yang H, et al. Clinical features and treatment outcomes of eosinophilic gastroenteritis: an analysis of 28 cases. Acta Gastroenterol Belg 2019; 82:5–10.
Yamada Y, Toki F, Yamamoto H, et al. Proton pump inhibitor treatment decreased duodenal and esophageal eosinophilia in a case of eosinophilic gastroenteritis. Allergol Int 2015; 64: (Suppl): S83–S85.
Untersmayr E, Bakos N, Schöll I, et al. Antiulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J 2005; 19:656–658.
Pineton de Chambrun G, Dufour G, Tassy B, et al. Diagnosis, natural history and treatment of eosinophilic enteritis: a review. Curr Gastroenterol Rep 2018; 20:37.
Grandinetti T, Biedermann L, Bussmann C, et al. Eosinophilic gastroenteritis: clinical manifestation, natural course, and evaluation of treatment with corticosteroids and vedolizumab. Dig Dis Sci 2019; 64:2231–2241.
Pineton de Chambrun G, Gonzalez F, Canva JY, et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol 2011; 9:950–956.
Fang S, Song Y, Zhang S, et al. Retrospective study of budesonide in children with eosinophilic gastroenteritis. Pediatr Res 2019; 86:505–509.
Lucendo AJ, Serrano-Montalbán B, Arias Á, et al. Efficacy of dietary treatment for inducing disease remission in eosinophilic gastroenteritis. J Pediatr Gastroenterol Nutr 2015; 61:56–64.
Rothenberg ME, Wen T, Greenberg A, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2015; 135:500–507.
Markowitz JE, Jobe L, Miller M, et al. Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis treated for 9 years. J Pediatr Gastroenterol Nutr 2018; 66:893–897.
Sastre J, Dávila I. Dupilumab: a new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol 2018; 28:139–150.
Kim HP, Reed CC, Herfarth HH, et al. Vedolizumab treatment may reduce steroid burden and improve histology in patients with eosinophilic gastroenteritis. Clin Gastroenterol Hepatol 2018; 16:1992–1994.